JY
NRIX icon

Jeff Yass’s Nurix Therapeutics NRIX Stock Holding History

Jeff Yass’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$924K Sell
38,080
-43,375
-53% -$739K ﹤0.01% 8393
2026
Q1 		$1.26M Buy
81,455
+30,902
+61% +$512K ﹤0.01% 7299
2025
Q4 		$959K Sell
50,553
-33,806
-40% -$486K ﹤0.01% 7291
2025
Q3 		$779K Sell
84,359
-6,561
-7% -$68.1K ﹤0.01% 7927
2025
Q2 		$1.04M Sell
90,920
-14,751
-14% -$159K ﹤0.01% 7341
2025
Q1 		$1.26M Buy
105,671
+55,985
+113% +$936K ﹤0.01% 6685
2024
Q4 		$936K Buy
49,686
+29,214
+143% +$670K ﹤0.01% 7132
2024
Q3 		$460K Sell
20,472
-36,719
-64% -$832K ﹤0.01% 8658
2024
Q2 		$1.19M Buy
57,191
+6,662
+13% +$104K ﹤0.01% 6165
2024
Q1 		$743K Sell
50,529
-22,011
-30% -$237K ﹤0.01% 7575
2023
Q4 		$749K Buy
72,540
+14,818
+26% +$102K ﹤0.01% 7704
2023
Q3 		$454K Sell
57,722
-33,159
-36% -$303K ﹤0.01% 8463
2023
Q2 		$908K Buy
90,881
+23,322
+35% +$238K ﹤0.01% 6908
2023
Q1 		$600K Buy
67,559
+42,793
+173% +$446K ﹤0.01% 8116
2022
Q4 		$272K Sell
24,766
-24,387
-50% -$294K ﹤0.01% 9335
2022
Q3 		$640K Buy
49,153
+33,378
+212% +$528K ﹤0.01% 7804
2022
Q2 		$200K Sell
15,775
-20,388
-56% -$231K ﹤0.01% 10631
2022
Q1 		$507K Sell
36,163
-5,751
-14% -$102K ﹤0.01% 8934
2021
Q4 		$1.21M Buy
41,914
+10,103
+32% +$306K ﹤0.01% 6767
2021
Q3 		$953K Buy
31,811
+4,596
+17% +$142K ﹤0.01% 7682
2021
Q2 		$722K Sell
27,215
-29,703
-52% -$872K ﹤0.01% 8667
2021
Q1 		$1.77M Buy
+56,918
New +$2.15M ﹤0.01% 6220

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's NRIX Position: Q2 2026 in Review

Jeff Yass reduced its Nurix Therapeutics (NRIX) stake by 53% in Q2 2026, selling an estimated $739K and leaving 38,080 shares worth $924K. The position accounts for ﹤0.01% of the portfolio, ranked #8393.

Jeff Yass first reported a position in NRIX in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.77M in Q1 2021. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Jeff Yass held 38,080 shares of Nurix Therapeutics worth $924K as of Q2 2026.
  • Jeff Yass sold 43,375 Nurix Therapeutics shares in Q2 2026, an estimated $739K.
  • Nurix Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8393 holding.
  • Jeff Yass first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Jeff Yass's Nurix Therapeutics position peaked at $1.77M in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.